Long-Term Cost-Effectiveness of Ideglira Versus Basal-Bolus Insulin As Intensification Therapies For People With Type 2 Diabetes Inadequately Controlled on Basal Insulin In Spain: Projections Based On The Dual VII Trial

FJ Ampudia; P Mezquita; A Ramirez de Arellano; A Basse; B Hunt

doi:10.1016/j.jval.2017.08.461

Long-Term Cost-Effectiveness of Ideglira Versus Basal-Bolus Insulin As Intensification Therapies For People With Type 2 Diabetes Inadequately Controlled on Basal Insulin In Spain: Projections Based On The Dual VII Trial

Value in Health ◽

10.1016/j.jval.2017.08.461 ◽

2017 ◽

Vol 20 (9) ◽

pp. A480 ◽

Cited By ~ 1

Author(s):

FJ Ampudia ◽

P Mezquita ◽

A Ramirez de Arellano ◽

A Basse ◽

B Hunt

Keyword(s):

Type 2 Diabetes ◽

Cost Effectiveness ◽

Basal Insulin ◽

Bolus Insulin ◽

Basal Bolus

Download Full-text

Long-Term Cost Utility Analysis Of Ideglira Versus Basal-Bolus Insulin Intensification Therapies In Patients With Type 2 Diabetes Inadequately Controlled On Basal Insulin In Spain

Value in Health ◽

10.1016/j.jval.2016.03.1712 ◽

2016 ◽

Vol 19 (3) ◽

pp. A99

Author(s):

M Prades ◽

L Lizan ◽

B Hunt ◽

A Ramirez de Arellano

Keyword(s):

Type 2 Diabetes ◽

Basal Insulin ◽

Cost Utility ◽

Cost Utility Analysis ◽

Utility Analysis ◽

Insulin Intensification ◽

Bolus Insulin ◽

Basal Bolus

Download Full-text

Switching to basal-bolus insulin therapy is effective and safe in long-term type 2 diabetes patients inadequately controlled with other insulin regimens

Endocrinología y Nutrición (English Edition) ◽

10.1016/j.endoen.2012.11.007 ◽

2013 ◽

Vol 60 (5) ◽

pp. 249-253

Author(s):

Irene Vinagre ◽

Juan Sánchez-Hernández ◽

José Luis Sánchez-Quesada ◽

Miguel Ángel María ◽

Alberto de Leiva ◽

...

Keyword(s):

Type 2 Diabetes ◽

Insulin Therapy ◽

Bolus Insulin ◽

Basal Bolus ◽

Term Type ◽

Diabetes Patients

Download Full-text

PDB55 Estimating the Cost-Effectiveness of Premixed Analog Insulin Versus Long Acting Analog Basal Insulin and Premixed Human Insulin in the Management of Type 2 Diabetes: A Long Term Analysis in the United Kingdom (UK)

Value in Health ◽

10.1016/j.jval.2012.03.976 ◽

2012 ◽

Vol 15 (4) ◽

pp. A180

Author(s):

B. Curtis ◽

R. Pollock ◽

J. Smith-Palmer ◽

W. Valentine

Keyword(s):

Type 2 Diabetes ◽

Cost Effectiveness ◽

Basal Insulin ◽

The United Kingdom ◽

Analog Insulin ◽

Long Acting ◽

The Cost ◽

Term Analysis

Download Full-text

DB1 EVALUATING THE COST-EFFECTIVENESS OF THERAPY CONVERSION FROM BASAL INSULIN TO BIPHASIC INSULIN ASPART 30/70 IN PATIENTS WITH TYPE 2 DIABETES IN CHINA: A MODELING STUDY OF LONG-TERM COSTS AND HEALTH OUTCOMES

Value in Health ◽

10.1016/s1098-3015(11)73078-9 ◽

2010 ◽

Vol 13 (7) ◽

pp. A507

Author(s):

J Chang ◽

F Sun ◽

H Li

Keyword(s):

Type 2 Diabetes ◽

Cost Effectiveness ◽

Health Outcomes ◽

Insulin Aspart ◽

Basal Insulin ◽

Biphasic Insulin ◽

Biphasic Insulin Aspart 30 ◽

The Cost

Download Full-text

Long-Term Cost Effectiveness Analysis Of Ideglira Versus Glp-1 Added To Basal Insulin As Intensification Therapies In Type 2 Diabetes Mellitus In Spain

Value in Health ◽

10.1016/j.jval.2016.03.1714 ◽

2016 ◽

Vol 19 (3) ◽

pp. A99

Author(s):

M Prades ◽

L Lizan ◽

B Hunt ◽

A Ramirez de Arellano

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Cost Effectiveness ◽

Basal Insulin ◽

Cost Effectiveness Analysis ◽

Effectiveness Analysis

Download Full-text

PDB74 - IDEGLIRA VERSUS IGLARLIXI FOR PATIENTS WITH INADEQUATELY CONTROLLED TYPE 2 DIABETES ON BASAL INSULIN: A LONG-TERM COST-EFFECTIVENESS ANALYSIS IN THE CZECH REPUBLIC

Value in Health ◽

10.1016/j.jval.2018.09.779 ◽

2018 ◽

Vol 21 ◽

pp. S130-S131

Author(s):

M. Russel-Szymczyk ◽

W. Parekh ◽

K. Rychna ◽

J. Pöhlmann ◽

B. Hunt

Keyword(s):

Type 2 Diabetes ◽

Czech Republic ◽

Cost Effectiveness ◽

Basal Insulin ◽

Cost Effectiveness Analysis ◽

The Czech Republic ◽

Effectiveness Analysis

Download Full-text

Comparison of the effect on Hyperglycemia and the Adverse Effects among Different GLP-1 Receptor Agonists Added to Basal Insulin and between GLP-1 Receptor Agonists and Basal Insulin Versus Basal-Plus or Basal-Bolus Insulin in Type 2 Diabetes: A Meta-Analysis

10.9734/bpi/nfmmr/v10/4105f ◽

2021 ◽

pp. 147-163

Author(s):

Andrey Emanuilov Manov ◽

Ashan Thomas Hatharasinghe ◽

Katrina Equinox Lopez

Keyword(s):

Type 2 Diabetes ◽

Adverse Effects ◽

Basal Insulin ◽

Meta Analysis ◽

Receptor Agonists ◽

Bolus Insulin ◽

Basal Bolus

Download Full-text

Modeling the Long-Term Cost-Effectiveness of IDegLira in Patients with Type 2 Diabetes Who are Failing To Meet Glycemic Targets on Basal Insulin Alone in The Netherlands

Diabetes Therapy ◽

10.1007/s13300-017-0266-3 ◽

2017 ◽

Vol 8 (4) ◽

pp. 753-765 ◽

Cited By ~ 10

Author(s):

Barnaby Hunt ◽

Divina Glah ◽

Maarten van der Vliet

Keyword(s):

Type 2 Diabetes ◽

Cost Effectiveness ◽

The Netherlands ◽

Basal Insulin ◽

Glycemic Targets

Download Full-text

Effect of basal insulin therapy with glargine U300 versus basal bolus insulin therapy in hospitalized patients with type 2 diabetes. Real-world study from India

Clinical Diabetology ◽

10.5603/dk.a2021.0011 ◽

2021 ◽

Author(s):

Asis Mitra ◽

Saswati Ray ◽

Sushma Jayan

Keyword(s):

Type 2 Diabetes ◽

Insulin Therapy ◽

Real World ◽

Basal Insulin ◽

Hospitalized Patients ◽

Bolus Insulin ◽

Basal Bolus

Download Full-text

Efficacy and Safety of IDegLira Versus Basal-Bolus Insulin Therapy in Patients With Type 2 Diabetes Uncontrolled on Metformin and Basal Insulin: The DUAL VII Randomized Clinical Trial

Diabetes Care ◽

10.2337/dc17-1114 ◽

2018 ◽

Vol 41 (5) ◽

pp. 1009-1016 ◽

Cited By ~ 63

Author(s):

Liana K. Billings ◽

Ankur Doshi ◽

Didier Gouet ◽

Alejandra Oviedo ◽

Helena W. Rodbard ◽

...

Keyword(s):

Type 2 Diabetes ◽

Clinical Trial ◽

Insulin Therapy ◽

Randomized Clinical Trial ◽

Basal Insulin ◽

Efficacy And Safety ◽

Bolus Insulin ◽

Basal Bolus

Download Full-text